NASDAQ:ELYM Eliem Therapeutics (ELYM) Stock Price, News & Analysis $8.18 -0.28 (-3.31%) (As of 03:07 PM ET) Add Compare Share Share Today's Range$8.03▼$8.6950-Day Range$5.81▼$8.9352-Week Range$2.35▼$11.55Volume158,736 shsAverage Volume415,499 shsMarket Capitalization$243.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Eliem Therapeutics alerts: Email Address Eliem Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish2.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingAcquiring Shares$49.95 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.26 out of 5 starsMedical Sector911th out of 927 stocksPharmaceutical Preparations Industry419th out of 425 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Eliem Therapeutics.Read more about Eliem Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.18% of the float of Eliem Therapeutics has been sold short.Short Interest Ratio / Days to CoverEliem Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Eliem Therapeutics has recently increased by 5.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEliem Therapeutics does not currently pay a dividend.Dividend GrowthEliem Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELYM. Previous Next 1.8 News and Social Media Coverage News SentimentEliem Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eliem Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ELYM on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eliem Therapeutics insiders have bought 2,238.07% more of their company's stock than they have sold. Specifically, they have bought $49,952,817.00 in company stock and sold $2,136,494.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Eliem Therapeutics is held by insiders.Percentage Held by Institutions69.76% of the stock of Eliem Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eliem Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eliem Therapeutics is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eliem Therapeutics is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEliem Therapeutics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Eliem Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> About Eliem Therapeutics Stock (NASDAQ:ELYM)Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Read More ELYM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELYM Stock News HeadlinesSeptember 11, 2024 | globenewswire.comEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitAugust 26, 2024 | globenewswire.comEliem Therapeutics Announces Additions to its Leadership TeamSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.August 14, 2024 | globenewswire.comEliem Therapeutics Reports Second Quarter Financial ResultsJuly 24, 2024 | finance.yahoo.comInsider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells SharesJuly 22, 2024 | benzinga.comIQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On MondayJuly 19, 2024 | sg.finance.yahoo.comInsider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...July 19, 2024 | finance.yahoo.comEVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)September 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.June 28, 2024 | globenewswire.comEliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® IndexesJune 27, 2024 | globenewswire.comEliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private PlacementMay 17, 2024 | benzinga.comEliem Therapeutics Stock (NASDAQ:ELYM), Earnings Estimates, EPS, and RevenueApril 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmApril 12, 2024 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 11, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODNApril 11, 2024 | finance.yahoo.comEliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines DealApril 11, 2024 | msn.comEnlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare moversApril 11, 2024 | markets.businessinsider.comEliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-marketSee More Headlines Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/16/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.03% Return on Assets-45.97% Debt Debt-to-Equity RatioN/A Current Ratio60.41 Quick Ratio60.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book2.10Miscellaneous Outstanding Shares29,752,000Free Float28,354,000Market Cap$243.37 million OptionableNot Optionable Beta-0.35 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Andrew Levin M.D. (Age 46)Ph.D., Principal Financial Officer & Executive Chairman Comp: $73kDr. Valerie Morisset Ph.D. (Age 54)Chief Scientific Officer and Executive VP of Research & Development Comp: $617.87kMs. Emily Pimblett (Age 40)Principal Accounting Officer Ms. Jo Palmer-Phillips Ph.D.Chief Development OfficerKey CompetitorsAltimmuneNASDAQ:ALTCOMPASS PathwaysNASDAQ:CMPSSage TherapeuticsNASDAQ:SAGEXBiotechNASDAQ:XBITCompugenNASDAQ:CGENView All CompetitorsInsiders & InstitutionsDriehaus Capital Management LLCSold 115,623 shares on 8/16/2024Ownership: 2.340%Affinity Asset Advisors LLCBought 1,670,661 shares on 8/15/2024Ownership: 5.615%Ally Bridge Group NY LLCBought 500,000 shares on 8/14/2024Ownership: 1.681%Renaissance Technologies LLCBought 26,383 shares on 8/9/2024Ownership: 0.124%Dimensional Fund Advisors LPBought 12,560 shares on 8/9/2024Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions ELYM Stock Analysis - Frequently Asked Questions How have ELYM shares performed this year? Eliem Therapeutics' stock was trading at $2.70 at the beginning of the year. Since then, ELYM shares have increased by 203.7% and is now trading at $8.20. View the best growth stocks for 2024 here. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.81) earnings per share (EPS) for the quarter. When did Eliem Therapeutics IPO? Eliem Therapeutics (ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO. Who are Eliem Therapeutics' major shareholders? Top institutional investors of Eliem Therapeutics include Affinity Asset Advisors LLC (5.62%), Driehaus Capital Management LLC (2.34%), Ally Bridge Group NY LLC (1.68%) and Renaissance Technologies LLC (0.12%). Insiders that own company stock include Ra Capital Management, LP, Valerie Morisset and Emily Pimblett. View institutional ownership trends. How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELYM) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
